Leicester spinout technology hailed as most commercially viable
A technology developed at the University, and the prime focus of Leicester spin-out company MIP Diagnostics, has been recognised as ‘most commercially viable’ at Europe’s flagship Drug Discovery event.
The annual ELRIG Drug Discovery conference, held at the Telford International Centre in September, is the largest Drug Discovery conference in Europe and featured a ‘Dragons’ Den’ competition. The coveted trophy is awarded to the product or service considered to be the most commercially viable and with the best prospects for generating significant revenues.
The ‘Dragons’ - Alan Fletcher, VP Reagents & New Markets at PerkinElmer; Ann Kramer, CEO of The Electrospinning Company; and Gary Allenby, CSO at Aurelia Bioscience – believed that the nanoMIP technology was "potentially disruptive" in the affinity reagent field due to the speed of delivery and robustness of the nanoMIPs (molecular imprinted polymers), sometime called 'plastic antibodies'.
The MIP technology is the result of extensive research led by Professor Sergey Piletsky from the Department of Chemistry.